Group 1 - Zelluna ASA successfully completed a private placement of 5,500,000 new shares, consisting of a first tranche of 3,729,774 shares and a second tranche of 1,770,226 shares, along with 315,639 shares allocated in a retail offering [1] - The share capital increase related to the issuance of 4,045,413 new shares has been registered, resulting in a new share capital of NOK 24,499,575, divided into 24,499,575 shares with a par value of NOK 1 each [2] Group 2 - Zelluna ASA is a biotechnology company focused on developing allogeneic 'off-the-shelf' T Cell Receptor-based Natural Killer (TCR-NK) cells for cancer treatment, combining NK cells' innate killing power with TCRs' precision targeting [3] - The company's lead program, ZI-MA4-1, targets the MAGE-A4 tumour antigen and is expected to enter clinical trials in 2026 [3]
Zelluna ASA: New share capital registered
Globenewswire·2025-11-17 09:33